Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03702231
Other study ID # 190001
Secondary ID 19-H-0001
Status Completed
Phase Phase 2
First received
Last updated
Start date December 7, 2018
Est. completion date July 12, 2023

Study information

Verified date February 2023
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: People who have cancer tend to get sick more often. This is in part because of the cancer treatments they get. Because of this, they may get shingles. Scientists had thought people with chronic lymphocytic leukemia (CLL) should not get the shingles vaccine. Now there is a new shingles vaccine that is not live and cannot cause shingles. The new shingles vaccine may protect people with weak immune systems from getting shingles. This is currently shown to be safe to give people 50 years and older to prevent shingles. Researchers want to test how safe the vaccine is and how it works in people with CLL. Objective: To learn how a new shingles vaccine works in people who have chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL). Eligibility: Adults ages 18 years and older with CLL or SLL who are not being treated for CLL or who are getting certain treatments. Design: Participants will be screened with a chart review or through another protocol. Visit 1 At visit 1, participants may have a pregnancy test, blood test, or physical exam. Pregnant participants cannot be in the study. Eligible participants will get the shingles vaccine as an injection. Participants will receive a diary and write down any symptoms they have for 7 days after the vaccines. Visit 2 Visit 2 will be 3 months later. Participants will have blood taken and get another dose of the vaccine. Participants will receive a diary and write down any symptoms they have for 7 days after the vaccines. Visit 3 Visit 3 will be 3 months after visit 2. Participants will have blood taken. Participants may be able to get an additional vaccine the same day as the shingles vaccine.


Description:

This study aims to determine the efficacy of the SHINGRIX varicella zoster virus (VZV) vaccine in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients that are treatment naive or receiving Bruton s-tyrosine kinase inhibitor (BTK-I). (Note: Since CLL and SLL are considered the same disease, CLL/SLL will be referred to as CLL hereafter, unless otherwise specified). Key Eligibility Criteria: - Diagnosis of CLL or SLL - Cohort 1: Treatment naive CLL or SLL patients - Cohort 2: Subjects must be receiving ibrutinib for at least 6 months prior to administration of the first vaccine dose - Cohort 3: Subjects must be receiving acalabrutinib for at least 6 months prior to administration of the first vaccine dose - Age greater than or equal to 18 years - ECOG performance status of 0-1 Design: Patients with CLL will enroll on the study for the purpose of determining the SHINGRIX vaccine efficacy in patients who are treatment naive or receiving BTK-I therapy. A series of 2 doses of SHINGRIX will be given at 0- and 3- month schedule by intramuscular injection. Subjects will be followed for 6 months and receive assessment of serologic response 6 months after the first vaccine dose administration. Study Objectives: Primary Objective: a)Determine the serologic response against VZV after completing the SHINGRIX (RZV) 2- dose vaccine series in the following populations: - CLL patients that are treatment naive (n=54) - CLL patients receiving treatment with ibrutinib (n=27) - CLL patients receiving treatment with acalabrutinib (n=27) Secondary Objective: a) Determine the safety and tolerability of the SHINGRIX vaccine among CLL patients who are treatment naive or receiving BTK-Is (ibrutinib or acalabrutinib).


Recruitment information / eligibility

Status Completed
Enrollment 116
Est. completion date July 12, 2023
Est. primary completion date September 9, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility - INCLUSION CRITERIA: - Diagnosis of CLL/SLL which is made according to the updated criteria of the NCI Working Group - Cohort 1:Treatment naive CLL/SLL patients - Cohort 2: Subjects must be receiving treatment ibrutinib for at least 6 months prior to administration of the first vaccine dose - Cohort 3: Subjects must be receiving acalabrutinib for at least 6 months prior to administration of the first vaccine dose - No active, symptomatic VZV or herpes zoster infection within 12 months prior to vaccination - No exposure to the live VZV vaccine (ZOSTAVAX) within 12 months prior to vaccination - No prior exposure to the SHINGRIX vaccine - Age greater than or equal to 18 years. - ECOG performance status of 0-2 - Able to comprehend the investigational nature of the protocol and provide informed consent EXCLUSION CRITERIA: - Female patients who are currently in pregnancy - Any uncontrolled active systemic infection - Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk - Severe allergic reaction to any component of SHINGRIX. - Received intravenous immunoglobulin (IVIG) within 3 months prior to vaccination. - Concomitant use of immunosuppressive agents (e.g. steroids, radio therapy, chemotherapy) - Hereditary or acquired immunodeficiency syndrome unrelated to chronic lymphocytic leukemia - Non-English speaking individuals will be excluded from the study

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Zoster Vaccine Recombinant, Adjuvanted
A series of 2 doses of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) will be given on a 0- and 3-month schedule by intramuscular injection.

Locations

Country Name City State
United States National Institutes of Health Clinical Center Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Varicella Zoster Virus (VZV) Seroprotective Titer Determine the rate of varicella zoster virus (VZV) seroprotective titer achievement in participants following completion of the SHINGRIX 2-dose vaccine series in Chronic Lymphocytic Leukemia (CLL) patients that are treatment naive or receiving therapy with a Bruton Tyrosine Kinase (BTK) Inhibitor (Ibrutinib or Acalabrutinib). The response criteria for achieving serologic response against VZV following the SHINGRIX vaccine are based on a validated luciferase immunoprecipitation assay detecting VZV antiglycoprotein E antibody. The primary endpoint is serologic response defined as = four-fold rises in VZV anti-gE blood. IgG titer achievement after completing the SHINGRIX (RZV) 2-dose vaccine series. 6 months after the first vaccine administration
Secondary Number of Participants That Experienced Serious Adverse Events Following the SHINGRIX Vaccine Among Chronic Lymphocytic Leukemia Patients. Determine the safety and tolerability of the SHINGRIX vaccine among Chronic Lymphocytic Leukemia (CLL) patients who are treatment naïve or receiving a Brutons-tyrosine kinase inhibitor (BTK-I) (Ibrutinib or Acalabrutinib). 6 months after the first vaccine administration
Secondary Number of Participants That Did Not Complete Study Due to Intolerance of the SHINGRIX Vaccine Among Chronic Lymphocytic Leukemia Patients. Determine the tolerability of the SHINGRIX vaccine among Chronic Lymphocytic Leukemia (CLL) patients who are treatment naïve or receiving a Brutons-tyrosine kinase inhibitor (BTK-I) (Ibrutinib or Acalabrutinib). 6 months after the first vaccine administration
See also
  Status Clinical Trial Phase
Recruiting NCT03588598 - Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies Phase 1
Recruiting NCT06043011 - Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Completed NCT02265731 - Study Evaluating Venetoclax in Subjects With Hematological Malignancies Phase 1/Phase 2
Completed NCT02582879 - informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
Completed NCT02553304 - Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patients
Completed NCT01419691 - Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Phase 2
Completed NCT01188681 - Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia Phase 1/Phase 2
Recruiting NCT04758975 - Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) Phase 2
Terminated NCT02914938 - A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Phase 1
Active, not recruiting NCT01976520 - Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Phase 1
Terminated NCT01463852 - A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL) Phase 0
Terminated NCT01203930 - A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL Phase 2
Recruiting NCT02966756 - A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Phase 2
Active, not recruiting NCT05105841 - Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Phase 2
Recruiting NCT04072458 - A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies Phase 1
Withdrawn NCT01754870 - Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Phase 2
Recruiting NCT01758042 - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders N/A
Completed NCT01885897 - IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Phase 1/Phase 2
Active, not recruiting NCT04830137 - A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Phase 1
Recruiting NCT03547115 - A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML Phase 1